Cargando…
Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
BACKGROUND: : In Taiwan, the vaccination program started in March 2021, with ChAdOx1-S being the first available WHO-approved COVID-19 vaccine, followed by Moderna vaccine. This study aimed to investigate the immunogenicity and safety of homologous and heterologous prime-boost regimens with ChAdOx1-...
Autores principales: | Kang, Chun-Min, Lee, Nan-Yao, Lin, Chih-Hsueh, Hsu, Yuan-Shan, Chang, Yu-Chang, Chung, Ming-Yi, Lee, Ya-Fan, Tseng, Wen-Pin, Wu, Jhong-Lin, Chen, Shey-Ying, Lu, Min-Chi, Ko, Wen-Chien, Lee, Ping-Ing, Hsueh, Po-Ren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986279/ https://www.ncbi.nlm.nih.gov/pubmed/35413588 http://dx.doi.org/10.1016/j.jcv.2022.105156 |
Ejemplares similares
-
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022) -
Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19
por: Kim, Dong-In, et al.
Publicado: (2022) -
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021) -
Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
por: Chang, Jer-Hwa, et al.
Publicado: (2022) -
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)